Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/PLK2_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PLK2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PLK2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PLK2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PLK2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PLK2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PLK2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00328862 | Prostate | BPH | regulation of microtubule-based process | 64/3107 | 240/18723 | 4.93e-05 | 5.11e-04 | 64 |
GO:00427706 | Prostate | BPH | signal transduction in response to DNA damage | 49/3107 | 172/18723 | 6.21e-05 | 6.23e-04 | 49 |
GO:00181059 | Prostate | BPH | peptidyl-serine phosphorylation | 79/3107 | 315/18723 | 7.09e-05 | 6.96e-04 | 79 |
GO:19028505 | Prostate | BPH | microtubule cytoskeleton organization involved in mitosis | 43/3107 | 147/18723 | 8.78e-05 | 8.27e-04 | 43 |
GO:00105946 | Prostate | BPH | regulation of endothelial cell migration | 61/3107 | 232/18723 | 1.13e-04 | 1.03e-03 | 61 |
GO:20001342 | Prostate | BPH | negative regulation of G1/S transition of mitotic cell cycle | 28/3107 | 84/18723 | 1.31e-04 | 1.18e-03 | 28 |
GO:00320929 | Prostate | BPH | positive regulation of protein binding | 28/3107 | 85/18723 | 1.65e-04 | 1.43e-03 | 28 |
GO:00105956 | Prostate | BPH | positive regulation of endothelial cell migration | 39/3107 | 133/18723 | 1.73e-04 | 1.48e-03 | 39 |
GO:00182097 | Prostate | BPH | peptidyl-serine modification | 82/3107 | 338/18723 | 1.73e-04 | 1.48e-03 | 82 |
GO:00070525 | Prostate | BPH | mitotic spindle organization | 36/3107 | 120/18723 | 1.83e-04 | 1.54e-03 | 36 |
GO:00457863 | Prostate | BPH | negative regulation of cell cycle | 91/3107 | 385/18723 | 2.10e-04 | 1.71e-03 | 91 |
GO:00026839 | Prostate | BPH | negative regulation of immune system process | 100/3107 | 434/18723 | 2.83e-04 | 2.20e-03 | 100 |
GO:00459303 | Prostate | BPH | negative regulation of mitotic cell cycle | 60/3107 | 235/18723 | 3.00e-04 | 2.32e-03 | 60 |
GO:00903982 | Prostate | BPH | cellular senescence | 29/3107 | 93/18723 | 3.66e-04 | 2.71e-03 | 29 |
GO:00315716 | Prostate | BPH | mitotic G1 DNA damage checkpoint | 13/3107 | 30/18723 | 5.11e-04 | 3.62e-03 | 13 |
GO:00070516 | Prostate | BPH | spindle organization | 48/3107 | 184/18723 | 6.91e-04 | 4.60e-03 | 48 |
GO:00448196 | Prostate | BPH | mitotic G1/S transition checkpoint | 13/3107 | 31/18723 | 7.48e-04 | 4.95e-03 | 13 |
GO:19019874 | Prostate | BPH | regulation of cell cycle phase transition | 89/3107 | 390/18723 | 8.17e-04 | 5.34e-03 | 89 |
GO:19028072 | Prostate | BPH | negative regulation of cell cycle G1/S phase transition | 28/3107 | 93/18723 | 8.54e-04 | 5.53e-03 | 28 |
GO:19021154 | Prostate | BPH | regulation of organelle assembly | 48/3107 | 186/18723 | 8.91e-04 | 5.72e-03 | 48 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLK2 | SNV | Missense_Mutation | | c.1468N>C | p.Asp490His | p.D490H | Q9NYY3 | protein_coding | deleterious(0.03) | benign(0.438) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PLK2 | SNV | Missense_Mutation | novel | c.1034N>A | p.Ser345Tyr | p.S345Y | Q9NYY3 | protein_coding | deleterious(0.04) | benign(0.212) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLK2 | SNV | Missense_Mutation | novel | c.412N>T | p.His138Tyr | p.H138Y | Q9NYY3 | protein_coding | deleterious(0.02) | possibly_damaging(0.808) | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLK2 | SNV | Missense_Mutation | novel | c.622C>G | p.Leu208Val | p.L208V | Q9NYY3 | protein_coding | deleterious(0.03) | possibly_damaging(0.879) | TCGA-OL-A5S0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxol | CR |
PLK2 | insertion | Frame_Shift_Ins | novel | c.1417_1418insCAAA | p.Asp473AlafsTer19 | p.D473Afs*19 | Q9NYY3 | protein_coding | | | TCGA-A8-A07G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
PLK2 | insertion | Nonsense_Mutation | novel | c.1416_1417insTAGGCCCCTAAAGATATCAGAAGCATAAAATTATAAA | p.Asp473Ter | p.D473* | Q9NYY3 | protein_coding | | | TCGA-A8-A07G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
PLK2 | insertion | Frame_Shift_Ins | novel | c.409_410insATTTACGACT | p.Leu137HisfsTer7 | p.L137Hfs*7 | Q9NYY3 | protein_coding | | | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLK2 | deletion | Frame_Shift_Del | novel | c.1327delN | p.Asp443MetfsTer5 | p.D443Mfs*5 | Q9NYY3 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
PLK2 | SNV | Missense_Mutation | novel | c.1961C>A | p.Thr654Asn | p.T654N | Q9NYY3 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-VS-A9UP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
PLK2 | SNV | Missense_Mutation | novel | c.1207N>G | p.Lys403Glu | p.K403E | Q9NYY3 | protein_coding | tolerated(1) | benign(0.001) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
10769 | PLK2 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | US8598172, 1 | | |
10769 | PLK2 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | inhibitor | 178102294 | BI-2536 | |
10769 | PLK2 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | inhibitor | 249565601 | ONVANSERTIB | |
10769 | PLK2 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | BI2536 | | |
10769 | PLK2 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | WORTMANNIN | WORTMANNIN | 17135248 |